Stay updated with breaking news from Molecure Sa. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Molecure files an Investigational New Drug (IND) application for lead clinical candidate OATD-01 with U.S. FDA ahead of a planned Phase 2 pulmonary sarcoidosis study· OATD-01 is a first in class chitotriosidase 1 (CHIT1) inhibitor with disease modifying potential in sarcoid...
30.03.2023 - Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress Entering 2023 with strong momentum and a robust pipeline of proprietary, first-in-class compoundsFirst patient dosed in Phase I trial with OATD-02, a novel, ... Seite 1
/PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to...
Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and ...
/PRNewswire/ -- Molecure S.A. ("Molecure": WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to...